Latest Regulatory Reform News

The Star Entertainment Group reported a 10% drop in H1 FY26 revenue, offset by a 71% improvement in EBITDA, while navigating ongoing licence suspensions and a critical refinancing process.

Australian Unity Limited reported increased revenue for the half-year ending December 2025, but earnings declined sharply due to inflationary pressures and ongoing transformation investments. The company also completed a leadership transition and strengthened its balance sheet.

Mercury NZ Limited reported a 130% surge in net profit for HY2026, driven by strong renewable generation and disciplined cost management, while advancing major geothermal and wind projects on schedule.

Chorus Limited has reported a strong half-year performance driven by fibre broadband growth, operational efficiencies, and a return to profitability, while launching initiatives to boost digital inclusion.

Challenger Limited reported a solid first half of FY26 with a 2% rise in normalised net profit after tax and record annuity sales. The company also announced a $150 million on-market share buy-back, reflecting confidence in its strong capital position.

WT Financial Group Limited has reported a robust 16.1% increase in net revenue for the half-year ending December 2025, underpinned by strategic acquisitions and a pioneering joint venture. The company’s proprietary AI technology and industry consolidation efforts position it well for continued expansion.

Ryman Healthcare has unveiled a refreshed strategy focused on growing recurring earnings and optimising its portfolio, targeting a $150 million sustainable cash flow improvement and $500 million cash release by FY29. The company plans to resume dividends from FY28, underpinned by a resilient balance sheet and disciplined capital management.

Avecho Biotechnology is on the cusp of completing patient dosing in its pivotal Phase III CBD insomnia trial, backed by a recent $2.5 million capital raise and patent allowances in the US and Europe.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Little Green Pharma welcomes a landmark US Executive Order directing cannabis rescheduling, a move poised to reshape the global medicinal cannabis landscape.

Regis Healthcare announces the resignation of CEO Dr Linda Mellors after six years, with a transition period underway as the board searches for her successor.

Aumake Limited has obtained a Hong Kong pharmaceutical wholesale licence, enabling it to launch up to five online over-the-counter medicine stores targeting Chinese consumers. This strategic move positions the company to tap into China’s rapidly expanding OTC market.